Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease subependymal giant cell astrocytoma
Symptom C0041341|tuberous sclerosis
Sentences 37
PubMedID- 25456370 Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised exist-1 study.
PubMedID- 24056156 Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors.
PubMedID- 25557360 Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
PubMedID- 23183057 The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex.
PubMedID- 25493579 The pathogenic activation of mtorc1 leads to the development of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
PubMedID- 25143481 Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex.
PubMedID- 22805244 Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 23158522 Interpretation: these results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis.
PubMedID- 23391693 Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations.
PubMedID- 24192699 Equally important avenues of molecular investigation might include inhibiting disease-causing pathways, such as the proposed use of rapamycin for subependymal giant cell astrocytomas in children with tuberous sclerosis;(83) upregulating affected proteins from homologous genes as in models of spinal muscular atrophy (84); or counteracting the downstream effects of a deficient protein, such as the proposed use of igf1 in children with duchenne’s dystrophy for review, please see liew, 2012 (85).
PubMedID- 23231513 In patients with subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce sega volume with good tolerability.
PubMedID- 26137524 Everolimus has since also been fda-approved for neuroendocrine tumors of pancreatic origin (pnet), breast carcinoma, and subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis.
PubMedID- 23138436 The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles.
PubMedID- 24756805 Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer.
PubMedID- 22136276 Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 24667738 The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.
PubMedID- 23743818 Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis.
PubMedID- 23404211 It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis .
PubMedID- 23686401 Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole.
PubMedID- 24105488 subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.
PubMedID- 21297924 From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas.
PubMedID- 26381530 Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619).
PubMedID- 23567018 Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
PubMedID- 20422196 The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis.
PubMedID- 25682485 Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period.
PubMedID- 24276039 Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus.
PubMedID- 24708766 The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma , progressive neuroendocrine tumors of pancreatic origin , subependymal giant cell astrocytoma associated with tuberous sclerosis , and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane .
PubMedID- 20643042 subependymal giant cell astrocytoma in tuberous sclerosis complex.
PubMedID- 25227171 Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
PubMedID- 22408430 Likewise, everolimus was approved by fda for the treatment of progressive endocrine tumours of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease and for patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (ts) (http://www.fda.gov).
PubMedID- 24244540 Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis –.
PubMedID- 24507694 Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
PubMedID- 20887114 Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex.
PubMedID- 24757527 Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc).
PubMedID- 20133820 Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
PubMedID- 23325902 Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc).
PubMedID- 22234227 Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature.

Page: 1